HRP20221516T1 - Derivati naftiridinona i njihova uporaba u liječenju aritmije - Google Patents
Derivati naftiridinona i njihova uporaba u liječenju aritmije Download PDFInfo
- Publication number
- HRP20221516T1 HRP20221516T1 HRP20221516TT HRP20221516T HRP20221516T1 HR P20221516 T1 HRP20221516 T1 HR P20221516T1 HR P20221516T T HRP20221516T T HR P20221516TT HR P20221516 T HRP20221516 T HR P20221516T HR P20221516 T1 HRP20221516 T1 HR P20221516T1
- Authority
- HR
- Croatia
- Prior art keywords
- chloro
- naphthyridin
- dichlorophenyl
- methyl
- hydroxymethyl
- Prior art date
Links
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000003416 antiarrhythmic agent Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- -1 -CH2CN Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- DDDSGZFENQKDDY-JTQLQIEISA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2S)-2,3-dihydroxypropoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC[C@H](CO)O DDDSGZFENQKDDY-JTQLQIEISA-N 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 2
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 claims 2
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 101500016415 Lophius americanus Glucagon-like peptide 1 Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- LFOZKAQFOKTGII-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-7-(methylamino)-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)NC)OCC(CO)O)=O)C LFOZKAQFOKTGII-UHFFFAOYSA-N 0.000 claims 1
- QHACNFMTZPBWRL-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-7-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)CC)OCC(CO)O)=O)C QHACNFMTZPBWRL-UHFFFAOYSA-N 0.000 claims 1
- OEYIWLUJHKVFFP-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-7-methoxy-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)OC)OCC(CO)O)=O)C OEYIWLUJHKVFFP-UHFFFAOYSA-N 0.000 claims 1
- PMNIPBGSJIEKQS-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-8-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=CC(=C12)CC)OCC(CO)O)=O)C PMNIPBGSJIEKQS-UHFFFAOYSA-N 0.000 claims 1
- LQMKJBAFJXVTEA-UHFFFAOYSA-N 1-(2-chloro-6-ethylphenyl)-5-(2,3-dihydroxypropoxy)-7-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)CC)N1C(=CC(C2=C(N=C(C=C12)CC)OCC(CO)O)=O)C LQMKJBAFJXVTEA-UHFFFAOYSA-N 0.000 claims 1
- JDMFEDXJXXQMKN-UHFFFAOYSA-N 1-[4-(3-amino-3-methylbut-1-ynyl)-2,6-dichlorophenyl]-8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound NC(C#CC1=CC(=C(C(=C1)Cl)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C)Cl)(C)C JDMFEDXJXXQMKN-UHFFFAOYSA-N 0.000 claims 1
- JEIFFJHSPMANBT-UHFFFAOYSA-N 3,5-dichloro-4-[2-methyl-4-oxo-5-(1H-pyrazol-5-yl)-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)C1=NNC=C1)=O)C)Cl JEIFFJHSPMANBT-UHFFFAOYSA-N 0.000 claims 1
- IOJQHMDFIWJXLF-UHFFFAOYSA-N 3,5-dichloro-4-[2-methyl-5-(1-methylpyrazol-4-yl)-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)C=1C=NN(C=1)C)=O)C)Cl IOJQHMDFIWJXLF-UHFFFAOYSA-N 0.000 claims 1
- OVOYJHPFWJNUQB-UHFFFAOYSA-N 3,5-dichloro-4-[5-(2-hydroxyethylamino)-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)NCCO)=O)C)Cl OVOYJHPFWJNUQB-UHFFFAOYSA-N 0.000 claims 1
- YHMZEOXOMITJAP-UHFFFAOYSA-N 3,5-dichloro-4-[5-(3-hydroxyazetidin-1-yl)-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)N1CC(C1)O)=O)C)Cl YHMZEOXOMITJAP-UHFFFAOYSA-N 0.000 claims 1
- FJJRZFWOCQMGEY-UHFFFAOYSA-N 3,5-dichloro-4-[5-[2-(1H-imidazol-5-yl)ethylamino]-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound N1C=NC(=C1)CCNC1=C2C(C=C(N(C2=CN=C1)C1=C(C=C(C#N)C=C1Cl)Cl)C)=O FJJRZFWOCQMGEY-UHFFFAOYSA-N 0.000 claims 1
- JTBFLNMQUBKHLQ-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound CC1=CC(=O)C2=C(OCC(O)CO)N=CC(Cl)=C2N1C1=C(Cl)C=C(C=C1Cl)C#N JTBFLNMQUBKHLQ-UHFFFAOYSA-N 0.000 claims 1
- XTTWQOXKGSVQSX-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-(2-hydroxyethoxyamino)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)NOCCO)=O)C)Cl XTTWQOXKGSVQSX-UHFFFAOYSA-N 0.000 claims 1
- NCMYMRCUTWGGJO-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)N1CCN(CC1)CCO)=O)C)Cl NCMYMRCUTWGGJO-UHFFFAOYSA-N 0.000 claims 1
- XNEUDCWKNMCPIY-GDBMZVCRSA-N 3,5-dichloro-4-[8-chloro-5-[[(3R,4S)-4-hydroxyoxolan-3-yl]amino]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)N[C@@H]1COC[C@H]1O)=O)C)Cl XNEUDCWKNMCPIY-GDBMZVCRSA-N 0.000 claims 1
- QTLNAOKNMRRSKL-UHFFFAOYSA-N 3-[[8-chloro-1-(2,6-dichlorophenyl)-2-methyl-4-oxo-1,6-naphthyridin-5-yl]amino]-2-hydroxy-N-(2-hydroxyethyl)propanamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NCC(C(=O)NCCO)O QTLNAOKNMRRSKL-UHFFFAOYSA-N 0.000 claims 1
- DCKMLYPIFNABIX-UHFFFAOYSA-N 3-chloro-2-[8-chloro-2-cyclopropyl-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C1CC1 DCKMLYPIFNABIX-UHFFFAOYSA-N 0.000 claims 1
- YFKJAUKINKKAPS-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C YFKJAUKINKKAPS-UHFFFAOYSA-N 0.000 claims 1
- RTXJBTFTKDIJGJ-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]-5-fluorobenzonitrile Chemical compound ClC=1C(=C(C#N)C=C(C=1)F)N1C(=CC(C2=C(N=CC(=C12)Cl)OCCOCCOCCOCCO)=O)C RTXJBTFTKDIJGJ-UHFFFAOYSA-N 0.000 claims 1
- HUMITMAJXKZKTO-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCCOCCOCCOCCO)=O)C HUMITMAJXKZKTO-UHFFFAOYSA-N 0.000 claims 1
- BKQQXYPCYMAYNN-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethylamino]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)NCCOCCOCCOCCO)=O)C BKQQXYPCYMAYNN-UHFFFAOYSA-N 0.000 claims 1
- TXBPZBKXZMRZAD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-5-(2,3-dihydroxypropoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)CO)=O)OCC(CO)O TXBPZBKXZMRZAD-UHFFFAOYSA-N 0.000 claims 1
- MHXJMDYNADZPBS-UHFFFAOYSA-N 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-5-(2-hydroxyethoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)CO)=O)OCCO MHXJMDYNADZPBS-UHFFFAOYSA-N 0.000 claims 1
- NEIITZWACZSJEY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(difluoromethyl)-5-(2,3-dihydroxypropoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C(F)F)=O)OCC(CO)O NEIITZWACZSJEY-UHFFFAOYSA-N 0.000 claims 1
- FJNDSSQBHOYCSW-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(2-methylsulfonylethylamino)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)NCCS(=O)(=O)C FJNDSSQBHOYCSW-UHFFFAOYSA-N 0.000 claims 1
- FWXGVUPQGGYNPO-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(3-hydroxypropyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCCO FWXGVUPQGGYNPO-UHFFFAOYSA-N 0.000 claims 1
- OSWNTPIKMGXESA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(oxetan-3-ylmethoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1COC1 OSWNTPIKMGXESA-UHFFFAOYSA-N 0.000 claims 1
- WUOZKIDPSWHTMY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-[2-(2-methoxyethoxy)ethoxy]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOC WUOZKIDPSWHTMY-UHFFFAOYSA-N 0.000 claims 1
- DBYLIOOXAAJUAD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-[[3-(hydroxymethyl)oxetan-3-yl]methoxy]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1(COC1)CO DBYLIOOXAAJUAD-UHFFFAOYSA-N 0.000 claims 1
- YRKPFBCMURMWHH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-6H-1,6-naphthyridine-4,5-dione Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)O YRKPFBCMURMWHH-UHFFFAOYSA-N 0.000 claims 1
- VXGWLTJUJVHZMV-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(1,2,4-triazol-1-yl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1N=CN=C1 VXGWLTJUJVHZMV-UHFFFAOYSA-N 0.000 claims 1
- BUFKMYQMAHJBHT-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(1-methyltetrazol-5-yl)oxy-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC1=NN=NN1C BUFKMYQMAHJBHT-UHFFFAOYSA-N 0.000 claims 1
- SNMWXWMIXVAIPH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(2,3,4-trihydroxybutoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C(CO)O)O SNMWXWMIXVAIPH-UHFFFAOYSA-N 0.000 claims 1
- PPOFRZAMNFVMDG-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(oxetan-3-ylmethoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC1COC1 PPOFRZAMNFVMDG-UHFFFAOYSA-N 0.000 claims 1
- XUENZROPARGQNH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-[(1-methyltetrazol-5-yl)amino]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC1=NN=NN1C XUENZROPARGQNH-UHFFFAOYSA-N 0.000 claims 1
- ITPBWSUVZDXXGH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-[(2-methyltetrazol-5-yl)amino]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC=1N=NN(N=1)C ITPBWSUVZDXXGH-UHFFFAOYSA-N 0.000 claims 1
- XDAYAPJRCGNDON-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C(CO)O XDAYAPJRCGNDON-UHFFFAOYSA-N 0.000 claims 1
- LHOYPFIGBFSNOS-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)O LHOYPFIGBFSNOS-UHFFFAOYSA-N 0.000 claims 1
- GJDHCQVTACKVML-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,3-dihydroxypropan-2-yloxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC(CO)CO GJDHCQVTACKVML-UHFFFAOYSA-N 0.000 claims 1
- ALXTXATYLGFTMA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxy-3-methylbutoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(C(C)(C)O)O ALXTXATYLGFTMA-UHFFFAOYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxy-3-methylbutoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C(C)(C)O)O XYYWOQHYDUCWCD-UHFFFAOYSA-N 0.000 claims 1
- DDDSGZFENQKDDY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(CO)O DDDSGZFENQKDDY-UHFFFAOYSA-N 0.000 claims 1
- OZAPVCJGIULPCZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-(methoxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)COC)=O)OCC(CO)O OZAPVCJGIULPCZ-UHFFFAOYSA-N 0.000 claims 1
- XSTIKDBUFTWNNB-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)O XSTIKDBUFTWNNB-UHFFFAOYSA-N 0.000 claims 1
- QGZGTAVFFSLXOZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridine-2-carbonitrile Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C#N)=O)OCC(CO)O QGZGTAVFFSLXOZ-UHFFFAOYSA-N 0.000 claims 1
- VCMAAYDSJJLABR-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxymethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)COCC(CO)O VCMAAYDSJJLABR-UHFFFAOYSA-N 0.000 claims 1
- NACUEOVEOGDGII-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC(CO)O NACUEOVEOGDGII-UHFFFAOYSA-N 0.000 claims 1
- HCTCNUKJFUGPRV-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)CC(CO)O HCTCNUKJFUGPRV-UHFFFAOYSA-N 0.000 claims 1
- WDGVFWSLMYEAGZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,4-dihydroxy-3-oxobutan-2-yl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(C)(C(CO)=O)O WDGVFWSLMYEAGZ-UHFFFAOYSA-N 0.000 claims 1
- LBUKDMRMXBBNPX-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxy-2-methylpropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C)(C)O LBUKDMRMXBBNPX-UHFFFAOYSA-N 0.000 claims 1
- HLIDCCUMHXLIRM-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyacetyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)=O HLIDCCUMHXLIRM-UHFFFAOYSA-N 0.000 claims 1
- LJRVXPVZQPEPBW-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCO LJRVXPVZQPEPBW-UHFFFAOYSA-N 0.000 claims 1
- VJWMFGICJZJHAO-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCCO VJWMFGICJZJHAO-UHFFFAOYSA-N 0.000 claims 1
- MHWBUIZVNLFKEP-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxyamino)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NOCCO MHWBUIZVNLFKEP-UHFFFAOYSA-N 0.000 claims 1
- LYJIYGZXENLAPE-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(3,4-dihydroxybutyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCC(CO)O LYJIYGZXENLAPE-UHFFFAOYSA-N 0.000 claims 1
- BSKNWGRELQKJMA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1OC(OC1)(C)C BSKNWGRELQKJMA-UHFFFAOYSA-N 0.000 claims 1
- DDDSGZFENQKDDY-SNVBAGLBSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2R)-2,3-dihydroxypropoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC[C@@H](CO)O DDDSGZFENQKDDY-SNVBAGLBSA-N 0.000 claims 1
- GMTMPGCBJCCSBJ-NEPJUHHUSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2R,4S)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1[C@H](C[C@@H](C1)O)CO GMTMPGCBJCCSBJ-NEPJUHHUSA-N 0.000 claims 1
- ZFFSQOGPNZWLRZ-GASCZTMLSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(3S,4R)-3,4-dihydroxypyrrolidin-1-yl]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1C[C@H]([C@H](C1)O)O ZFFSQOGPNZWLRZ-GASCZTMLSA-N 0.000 claims 1
- BMSQSCMJMBTGSK-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[2-(1H-imidazol-5-yl)ethylamino]-2-methyl-1,6-naphthyridin-4-one Chemical compound N1C=NC(=C1)CCNC1=C2C(C=C(N(C2=C(C=N1)Cl)C1=C(C=CC=C1Cl)Cl)C)=O BMSQSCMJMBTGSK-UHFFFAOYSA-N 0.000 claims 1
- IKPDCTPBFIIQRF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(COCC(CO)O)O IKPDCTPBFIIQRF-UHFFFAOYSA-N 0.000 claims 1
- MGUUTBZGBKDYFF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-2-methyl-1,7-naphthyridin-4-one Chemical compound CC1=CC(=O)C2=C(OCC(CO)(CO)CO)C=NC(Cl)=C2N1C1=C(Cl)C=CC=C1Cl MGUUTBZGBKDYFF-UHFFFAOYSA-N 0.000 claims 1
- SJJQFMZJSMAXHL-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)(C)CO SJJQFMZJSMAXHL-UHFFFAOYSA-N 0.000 claims 1
- MREYLDDLEGSHRF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)propoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(CO)CO MREYLDDLEGSHRF-UHFFFAOYSA-N 0.000 claims 1
- TUKPJFKLDJTXDD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)propoxy]-2-(methoxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)COC)=O)OCC(CO)CO TUKPJFKLDJTXDD-UHFFFAOYSA-N 0.000 claims 1
- SCIZOVDYSFRBNZ-JTQLQIEISA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[[(2S)-2,3-dihydroxypropyl]amino]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC[C@@H](CO)O SCIZOVDYSFRBNZ-JTQLQIEISA-N 0.000 claims 1
- KWKBWPLUKPGJCR-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-(3-morpholin-4-ylprop-1-ynyl)phenyl]-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN1CCOCC1)Cl)C)=O)OCCO KWKBWPLUKPGJCR-UHFFFAOYSA-N 0.000 claims 1
- SYWRDVNCTMJCFH-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)prop-1-ynyl]phenyl]-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN1CCS(CC1)(=O)=O)Cl)C)=O)OCCO SYWRDVNCTMJCFH-UHFFFAOYSA-N 0.000 claims 1
- YLYMIVSKYAHRGN-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-[3-(dimethylamino)prop-1-ynyl]phenyl]-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN(C)C)Cl)C)=O)OCC1OC(OC1)(C)C YLYMIVSKYAHRGN-UHFFFAOYSA-N 0.000 claims 1
- PGJVAYQMCYJFFH-UHFFFAOYSA-N 8-cyclopropyl-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound C1(CC1)C=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)O PGJVAYQMCYJFFH-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- BAKFDWZBSGAYAR-UHFFFAOYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)C)=O)OCCOCCOCCOCCO Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)C)=O)OCCOCCOCCOCCO BAKFDWZBSGAYAR-UHFFFAOYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-HNNXBMFYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@@H](C(C)(C)O)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@@H](C(C)(C)O)O XYYWOQHYDUCWCD-HNNXBMFYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-OAHLLOKOSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@H](C(C)(C)O)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@H](C(C)(C)O)O XYYWOQHYDUCWCD-OAHLLOKOSA-N 0.000 claims 1
- LYJIYGZXENLAPE-NSHDSACASA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O LYJIYGZXENLAPE-NSHDSACASA-N 0.000 claims 1
- LYJIYGZXENLAPE-LLVKDONJSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O LYJIYGZXENLAPE-LLVKDONJSA-N 0.000 claims 1
- NACUEOVEOGDGII-JTQLQIEISA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O NACUEOVEOGDGII-JTQLQIEISA-N 0.000 claims 1
- NACUEOVEOGDGII-SNVBAGLBSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O NACUEOVEOGDGII-SNVBAGLBSA-N 0.000 claims 1
- PCMMBCZCYFFFPN-UHFFFAOYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOCCOCCO Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOCCOCCO PCMMBCZCYFFFPN-UHFFFAOYSA-N 0.000 claims 1
- XDAYAPJRCGNDON-CYBMUJFWSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O XDAYAPJRCGNDON-CYBMUJFWSA-N 0.000 claims 1
- XDAYAPJRCGNDON-ZDUSSCGKSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@H](CO)O XDAYAPJRCGNDON-ZDUSSCGKSA-N 0.000 claims 1
- 208000016998 Conn syndrome Diseases 0.000 claims 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 229940082863 Factor VIIa inhibitor Drugs 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 108091007911 GSKs Proteins 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 claims 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- OUAHAENHSCFBMK-UHFFFAOYSA-N N-[1-(2,6-dichloro-4-cyanophenyl)-2-methyl-4-oxo-1,7-naphthyridin-5-yl]-1H-pyrazole-4-sulfonamide Chemical compound ClC1=C(C(=CC(=C1)C#N)Cl)N1C(=CC(C2=C(C=NC=C12)NS(=O)(=O)C=1C=NNC=1)=O)C OUAHAENHSCFBMK-UHFFFAOYSA-N 0.000 claims 1
- DPUOOLDBTIZYJV-UHFFFAOYSA-N N-[2-[[1-(2,6-dichloro-4-cyanophenyl)-2-methyl-4-oxo-1,7-naphthyridin-5-yl]amino]ethyl]methanesulfonamide Chemical compound ClC1=C(C(=CC(=C1)C#N)Cl)N1C(=CC(C2=C(C=NC=C12)NCCNS(=O)(=O)C)=O)C DPUOOLDBTIZYJV-UHFFFAOYSA-N 0.000 claims 1
- MEDIMLKAXOOFGC-UHFFFAOYSA-N N-[2-[[8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-4-oxo-1,6-naphthyridin-5-yl]oxy]ethyl]methanesulfonamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCNS(=O)(=O)C MEDIMLKAXOOFGC-UHFFFAOYSA-N 0.000 claims 1
- YBFIRRLWTMWYQM-UHFFFAOYSA-N N-[2-[[8-chloro-1-(2,6-dichlorophenyl)-2-methyl-4-oxo-1,6-naphthyridin-5-yl]oxy]ethyl]methanesulfonamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCCNS(=O)(=O)C YBFIRRLWTMWYQM-UHFFFAOYSA-N 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 108091006299 SLC2A2 Proteins 0.000 claims 1
- 206010040639 Sick sinus syndrome Diseases 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- RTZDPYBYXWKQFY-UHFFFAOYSA-N [8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridin-2-yl]methyl dihydrogen phosphate Chemical compound P(=O)(OCC=1N(C2=C(C=NC(=C2C(C=1)=O)OCC(CO)O)Cl)C1=C(C=CC=C1Cl)Cl)(O)O RTZDPYBYXWKQFY-UHFFFAOYSA-N 0.000 claims 1
- 230000009102 absorption Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 claims 1
- 239000000464 adrenergic agent Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 150000001539 azetidines Chemical group 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 1
- 239000000859 incretin Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000003228 microsomal effect Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000004885 piperazines Chemical group 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000013846 primary aldosteronism Diseases 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003235 pyrrolidines Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000009103 reabsorption Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410930P | 2016-10-21 | 2016-10-21 | |
| CN2016102928 | 2016-10-21 | ||
| US201662413292P | 2016-10-26 | 2016-10-26 | |
| EP17801105.2A EP3529251B1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
| PCT/IB2017/056515 WO2018073788A1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221516T1 true HRP20221516T1 (hr) | 2023-02-17 |
Family
ID=60409317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221516TT HRP20221516T1 (hr) | 2016-10-21 | 2017-10-19 | Derivati naftiridinona i njihova uporaba u liječenju aritmije |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10266531B2 (enExample) |
| EP (2) | EP4141006A1 (enExample) |
| JP (1) | JP7030802B2 (enExample) |
| KR (1) | KR102540872B1 (enExample) |
| CN (1) | CN109843887B (enExample) |
| AU (2) | AU2017344489C1 (enExample) |
| CL (1) | CL2019001023A1 (enExample) |
| CO (1) | CO2019003894A2 (enExample) |
| CR (1) | CR20190201A (enExample) |
| CU (1) | CU24599B1 (enExample) |
| DO (1) | DOP2019000100A (enExample) |
| EC (1) | ECSP19026973A (enExample) |
| ES (1) | ES2934234T3 (enExample) |
| FI (1) | FI3529251T3 (enExample) |
| HR (1) | HRP20221516T1 (enExample) |
| HU (1) | HUE060882T2 (enExample) |
| IL (1) | IL266128B (enExample) |
| JO (1) | JOP20190086A1 (enExample) |
| LT (1) | LT3529251T (enExample) |
| MX (1) | MX390044B (enExample) |
| PE (1) | PE20190735A1 (enExample) |
| PH (1) | PH12019500849A1 (enExample) |
| PL (1) | PL3529251T3 (enExample) |
| PT (1) | PT3529251T (enExample) |
| RS (1) | RS63841B1 (enExample) |
| SA (1) | SA519401614B1 (enExample) |
| SG (1) | SG11201902529WA (enExample) |
| SI (1) | SI3529251T1 (enExample) |
| TW (1) | TWI759343B (enExample) |
| UY (1) | UY37445A (enExample) |
| WO (1) | WO2018073788A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CN112585139B (zh) * | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| WO2022074567A1 (en) * | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
| CN115677739B (zh) * | 2021-07-31 | 2025-09-30 | 华南理工大学 | 一种o,o-二氟化硼配合物的制备方法 |
| AR127698A1 (es) * | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| US20260092074A1 (en) * | 2022-09-23 | 2026-04-02 | Guangzhou Vinnocent Pharmaceutical Limited | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof |
| KR20260015867A (ko) * | 2023-05-24 | 2026-02-03 | 노파르티스 아게 | 질환 또는 장애 치료용 나프티리디논 유도체 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
| JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
| JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| FI77669C (fi) | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
| US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
| US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| EP0787720B1 (en) | 1994-10-20 | 2003-07-16 | Wakunaga Seiyaku Kabushiki Kaisha | Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient |
| PT897919E (pt) | 1996-04-19 | 2004-11-30 | Wakunaga Pharma Co Ltd | Novos derivados do acido piridonacarboxilico ou seus sais e agentes anti-bacterianos contendo-os como ingrediente activo |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6136823A (en) | 1996-11-28 | 2000-10-24 | Wakunaga Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient |
| JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| AU5509099A (en) | 1998-08-03 | 2000-02-28 | Basf Corporation | Pyridinones for the treatment of sexual dysfunction |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6683113B2 (en) | 1999-09-23 | 2004-01-27 | Pharmacia Corporation | (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| HUP0301335A3 (en) | 2000-04-12 | 2006-02-28 | Novartis Ag | Combination of organic compounds |
| JP2003040866A (ja) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤 |
| CN1578781A (zh) * | 2001-09-26 | 2005-02-09 | 拜尔药品公司 | 用作抗糖尿病药物的1,8－萘啶衍生物 |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| JP2005529160A (ja) | 2002-05-31 | 2005-09-29 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物 |
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
| WO2005026164A1 (en) | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Pharmacologically active imidazo[4,5-c]pyridines |
| JP4719681B2 (ja) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | キナゾリンカリウムチャネル阻害剤 |
| JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| JP5179174B2 (ja) | 2004-05-28 | 2013-04-10 | ノバルティス ファーマ アーゲー | アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体 |
| CA2568164A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
| JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 |
| TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| CA2660701A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| EP2094669A2 (en) | 2006-12-18 | 2009-09-02 | Novartis AG | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| KR20090090395A (ko) | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
| RU2009139811A (ru) | 2007-03-29 | 2011-05-10 | Новартис АГ (CH) | Гетероциклические спиросоединения |
| ES2494366T3 (es) * | 2008-02-22 | 2014-09-15 | Otsuka Pharmaceutical Co., Ltd. | Compuesto de benzodiacepina y composición farmacéutica |
| WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
| KR20130059400A (ko) | 2010-08-25 | 2013-06-05 | (주)네오팜 | 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물 |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| ES2561298T3 (es) | 2011-07-12 | 2016-02-25 | F. Hoffmann-La Roche Ag | Compuestos de aminometilquinolona |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| EP2855472B1 (en) | 2012-04-05 | 2016-09-14 | Boehringer Ingelheim International GmbH | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
| US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014152317A2 (en) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
| AR096022A1 (es) | 2013-04-11 | 2015-12-02 | Basf Se | Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales |
| WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
| US20160326165A1 (en) | 2013-12-26 | 2016-11-10 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/ar unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/es not_active Application Discontinuation
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/hr unknown
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/es unknown
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/lt unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/pl unknown
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/hu unknown
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 CU CU2019000042A patent/CU24599B1/es unknown
- 2017-10-19 MX MX2019004484A patent/MX390044B/es unknown
- 2017-10-19 ES ES17801105T patent/ES2934234T3/es active Active
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/zh active Active
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/ko active Active
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 TW TW106135836A patent/TWI759343B/zh active
- 2017-10-19 SI SI201731279T patent/SI3529251T1/sl unknown
- 2017-10-19 RS RS20221152A patent/RS63841B1/sr unknown
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 PT PT178011052T patent/PT3529251T/pt unknown
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en not_active Ceased
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/fi active
- 2017-10-19 CR CR20190201A patent/CR20190201A/es unknown
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/ja active Active
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/es unknown
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/es unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/es unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/es unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/ar unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221516T1 (hr) | Derivati naftiridinona i njihova uporaba u liječenju aritmije | |
| JP2019531326A5 (enExample) | ||
| TWI894413B (zh) | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 | |
| JP7653441B2 (ja) | Ｔ細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物 | |
| ES2234097T3 (es) | Ftalazinas con actividad inhibidora de la angiogenesis. | |
| JP4722851B2 (ja) | キノリンカリウムチャネル阻害剤 | |
| JP4801335B2 (ja) | 抗新生物薬としての２，４，ジ（ヘテロ−）アリールアミノ（−オキシ）−５−置換ピリミジン | |
| CN102036963B (zh) | 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物 | |
| CN105593224B (zh) | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 | |
| KR100782091B1 (ko) | 배변을 촉진하는 의약 조성물 | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| AU2021257373B2 (en) | Pyridopyrimidinone derivatives and their use as Aryl hydrocarbon receptor modulators | |
| EA026977B1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| TW201803854A (zh) | 經胺取代之芳基或雜芳基化合物 | |
| KR20120044966A (ko) | 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도 | |
| EP1608631A2 (en) | Bi-cyclic pyrimidine inhibitors of tgf beta | |
| PT1303496E (pt) | Derivados de pirimidina | |
| KR20070034524A (ko) | 무스카린 수용체 조정자 | |
| MX2010013919A (es) | Derivados de pirrolopiridinil-pirimidin-2-il-amina. | |
| KR20080049130A (ko) | 세포 증식 억제 활성을 갖는 이미다조 [1,2-ａ] 피리딘 | |
| WO2016102493A1 (en) | Imidazopyridine ezh2 inhibitors | |
| MXPA02012943A (es) | Compuestos de cinolina. | |
| CN110872296B (zh) | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 | |
| US7579344B2 (en) | Pyrimidine derivatives possessing cell-cycle inhibitors activity | |
| US12440494B2 (en) | Compounds useful for inhibiting RAF dimers |